Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

The P2X7 Receptor: A Key Player in Immune-Mediated Bone Loss?

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Sorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerability

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Predictors of effects of lifestyle intervention on diabetes mellitus type 2 patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Multiple Fractures and Impaired Bone Fracture Healing in a Patient with Pycnodysostosis and Hypophosphatasia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Bone turnover markers in children and adolescents with type 1 diabetes-A systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Role of the purinergic P2X receptors in osteoclast pathophysiology

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

Inflammatory diseases are often multiorganic diseases with manifestations not related directly to the primary affected organ. They are often complicated by a generalized bone loss that subsequently leads to osteoporosis and bone fractures. The exact mechanism for the accompanying bone loss is not understood in full detail, but factors such as glucocorticoid treatment, immobilization, malnutrition, and insufficient intake of vitamin D play a role. However, it has become evident that the inflammatory process itself is involved and the resulting bone loss is termed immune-mediated bone loss. It stems from an increase in bone resorption and the pro-inflammatory cytokines tumor necrosis factor alpha and interleukin 1 beta and has been shown to not only mediate the inflammatory response but also to strongly stimulate bone degradation. The purinergic P2X7 receptor is central in the processing of these two cytokines and in the initiation of the inflammatory response, and it is a key molecule in the regulation of both bone formation and bone resorption. The aim of this review is therefore to provide evidence-based novel hypotheses of the role of ATP-mediated purinergic signalling via the P2X7 receptor in immune-mediated bone loss and -osteoporosis.

OriginalsprogEngelsk
TidsskriftTheScientificWorldJournal
Vol/bind2014
Sider (fra-til)954530
ISSN1537-744X
DOI
StatusUdgivet - 2014

ID: 43540290